Under-the-radar NiKang Therapeutics bursts onto the scene with $200M Series C from investors that screams IPO
A secretive biotech out of Wilmington, DE, closed a massive, nine-figure Series C on Wednesday, and it comes from an investor syndicate that is highly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
